589 related articles for article (PubMed ID: 36791069)
1. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study.
Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M
PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
3. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
4. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
5. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
6. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
7. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
8. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
[TBL] [Abstract][Full Text] [Related]
10. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
[TBL] [Abstract][Full Text] [Related]
11. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
[TBL] [Abstract][Full Text] [Related]
12. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
Stellini R; Gianello R; Gomarasca W
Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
[TBL] [Abstract][Full Text] [Related]
13. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
14. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
16. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
Oliveira-Silva J; Reis T; Lopes C; Batista-Silva R; Ribeiro R; Marques G; Pacheco V; Rodrigues T; Afonso A; Pinheiro V; Araújo L; Rodrigues F; Antunes I
Vaccine; 2022 Jan; 40(4):650-655. PubMed ID: 34952755
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
[TBL] [Abstract][Full Text] [Related]
18. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
20. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
Front Immunol; 2022; 13():909910. PubMed ID: 35784321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
